Lavipharm S.A (LAVI) - Cash Flow Conversion Efficiency

Latest as of December 2022: 0.013x

Based on the latest financial reports, Lavipharm S.A (LAVI) has a cash flow conversion efficiency ratio of 0.013x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€527.00K ≈ $616.12K USD) by net assets (€40.28 Million ≈ $47.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LAVI company net worth for the company's overall valuation and market capitalisation.

Lavipharm S.A - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Lavipharm S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Lavipharm S.A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lavipharm S.A ranked by their cash flow conversion efficiency. Explore Lavipharm S.A cash earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Taiwan Hopax Chemsistry MFG Co Ltd TWO:6509	0.035x
Microtek International Inc TW:2305	0.027x
Aten International Co Ltd TW:6277	0.034x
Lionheart Holdings Unit NASDAQ:CUBWU	-0.001x
Nongshim Holdi KO:072710	0.015x
Arbonia AG SW:ARBN	0.049x
Shenzhen Sine Electric Co. Ltd. A SHG:688395	0.031x
Valuetronics Holdings Limited F:GJ7	0.021x

Annual Cash Flow Conversion Efficiency for Lavipharm S.A (2014–2024)

The table below shows the annual cash flow conversion efficiency of Lavipharm S.A from 2014 to 2024. View LAVI share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€52.97 Million ≈ $61.92 Million	€4.64 Million ≈ $5.42 Million	0.088x	+1219.29%
2023-12-31	€42.77 Million ≈ $50.00 Million	€284.00K ≈ $332.03K	0.007x	-92.01%
2022-12-31	€40.28 Million ≈ $47.09 Million	€3.35 Million ≈ $3.91 Million	0.083x	+121.62%
2021-12-31	€-9.94 Million ≈ $-11.62 Million	€3.82 Million ≈ $4.46 Million	-0.384x	-65.91%
2020-12-31	€-12.30 Million ≈ $-14.38 Million	€2.85 Million ≈ $3.33 Million	-0.232x	-15.32%
2019-12-31	€-14.40 Million ≈ $-16.84 Million	€2.89 Million ≈ $3.38 Million	-0.201x	-176.84%
2018-12-31	€-19.53 Million ≈ $-22.83 Million	€1.42 Million ≈ $1.66 Million	-0.073x	+4.54%
2017-12-31	€-19.92 Million ≈ $-23.29 Million	€1.51 Million ≈ $1.77 Million	-0.076x	-299.17%
2016-12-31	€-31.82 Million ≈ $-37.21 Million	€606.00K ≈ $708.48K	-0.019x	-112.96%
2015-12-31	€-64.42 Million ≈ $-75.31 Million	€576.00K ≈ $673.40K	-0.009x	+81.60%
2014-12-31	€-48.96 Million ≈ $-57.24 Million	€2.38 Million ≈ $2.78 Million	-0.049x	--

About Lavipharm S.A

AT:LAVI Greece Drug Manufacturers - Specialty & Generic

Market Cap

$312.25 Million

€267.09 Million EUR

Market Cap Rank

#15097 Global

#40 in Greece

Share Price

€1.58

Change (1 day)

+2.07%

52-Week Range

€0.78 - €1.70

All Time High

€2.05